Healthequity Stock Alpha and Beta Analysis
| HQY Stock | USD 104.25 0.40 0.38% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as HealthEquity. It also helps investors analyze the systematic and unsystematic risks associated with investing in HealthEquity over a specified time horizon. Remember, high HealthEquity's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to HealthEquity's market risk premium analysis include:
Beta 1.8 | Alpha 0.29 | Risk 2.26 | Sharpe Ratio 0.23 | Expected Return 0.51 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
HealthEquity |
HealthEquity Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. HealthEquity market risk premium is the additional return an investor will receive from holding HealthEquity long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in HealthEquity. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate HealthEquity's performance over market.| α | 0.29 | β | 1.80 |
HealthEquity expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of HealthEquity's Buy-and-hold return. Our buy-and-hold chart shows how HealthEquity performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.HealthEquity Market Price Analysis
Market price analysis indicators help investors to evaluate how HealthEquity stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading HealthEquity shares will generate the highest return on investment. By understating and applying HealthEquity stock market price indicators, traders can identify HealthEquity position entry and exit signals to maximize returns.
HealthEquity Return and Market Media
The median price of HealthEquity for the period between Sun, Aug 25, 2024 and Sat, Nov 23, 2024 is 83.83 with a coefficient of variation of 10.04. The daily time series for the period is distributed with a sample standard deviation of 8.55, arithmetic mean of 85.17, and mean deviation of 6.83. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 1727 shares by Elimelech Rosner of HealthEquity at 83.6769 subject to Rule 16b-3 | 09/06/2024 |
2 | HQY vs. MEDP Which Stock Is the Better Value Option | 09/10/2024 |
3 | Disposition of 12296 shares by Elimelech Rosner of HealthEquity at 77.0242 subject to Rule 16b-3 | 09/13/2024 |
4 | Disposition of 1511 shares by Jon Kessler of HealthEquity at 78.9334 subject to Rule 16b-3 | 09/16/2024 |
5 | New Research Findings Reveal Employers Who Contribute to HSAs See Double-Digit Growth in Employee Participation | 09/26/2024 |
6 | Disposition of 1247 shares by Corvino Frank of HealthEquity at 80.2645 subject to Rule 16b-3 | 10/01/2024 |
7 | Disposition of 7500 shares by Selander Robert W of HealthEquity at 21.27 subject to Rule 16b-3 | 10/09/2024 |
8 | HealthEquitys investors will be pleased with their decent 52 percent return over the last five years | 10/15/2024 |
9 | EW Q3 Earnings Match Estimates, Revenues Miss, Stock Falls | 10/25/2024 |
10 | In-Depth Analysis UnitedHealth Group Versus Competitors In Health Care Providers Services Industry | 10/30/2024 |
11 | Heres Why HealthEquity is a Strong Growth Stock | 10/31/2024 |
12 | HealthEquity Clears Key Benchmark, Hitting 80-Plus RS Rating | 11/04/2024 |
13 | HSIC Q3 Earnings Top, Margins Down, Stock Gains in Premarket | 11/05/2024 |
14 | STE Q2 Earnings Beat Estimates, Margins Dip, Stock Gains in Aftermarket | 11/07/2024 |
15 | HealthEquity announces retirement of CEO Jon Kessler | 11/12/2024 |
16 | Acquisition by Stephen Neeleman of 24188 shares of HealthEquity at 14.0 subject to Rule 16b-3 | 11/14/2024 |
17 | Heres Why You Should Add HealthEquity Stock to Your Portfolio Now - MSN | 11/20/2024 |
About HealthEquity Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including HealthEquity or other stocks. Alpha measures the amount that position in HealthEquity has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 0.07 | 0.0735 | Price To Sales Ratio | 6.47 | 6.57 |
HealthEquity Upcoming Company Events
As portrayed in its financial statements, the presentation of HealthEquity's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, HealthEquity's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of HealthEquity's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of HealthEquity. Please utilize our Beneish M Score to check the likelihood of HealthEquity's management manipulating its earnings.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 3rd of June 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 31st of January 2023 Last Financial Announcement | View |
Build Portfolio with HealthEquity
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for HealthEquity Stock Analysis
When running HealthEquity's price analysis, check to measure HealthEquity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HealthEquity is operating at the current time. Most of HealthEquity's value examination focuses on studying past and present price action to predict the probability of HealthEquity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HealthEquity's price. Additionally, you may evaluate how the addition of HealthEquity to your portfolios can decrease your overall portfolio volatility.